Prothena Corporation is a late-stage clinical biotechnology company headquartered in San Francisco, California, focused on developing novel therapies for devastating diseases including Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Founded in 2005 as a spinout from Elan Corporation, Prothena has leveraged expertise in protein dynamics and aggregation to build a pipeline of antibody-based therapeutics.
PRX005 is Prothena's lead tau-targeted therapeutic candidate, an anti-tau monoclonal antibody designed to target the microtubule-binding region (MTBR) of tau protein. The MTBR region is critically involved in tau aggregation and cell-to-cell propagation of pathology.
PRX005 binds to a specific epitope within the MTBR of tau that is implicated in:
By targeting the MTBR rather than the N-terminal region (as earlier antibodies did), PRX005 is designed to directly inhibit the aggregation-prone region of tau and block the spread of pathological tau species.
PRX005 is in early clinical development for Alzheimer's disease. The program represents Prothena's entry into the tau antibody space, competing with programs from Biogen (BIIB080), Eisai (E2814), and others.
| Compound | Indication | Mechanism | Phase | Status |
|---|---|---|---|---|
| PRX005 | AD | Anti-tau MTBR antibody | Early clinical | Active |
Prothena has a history of alpha-synuclein programs:
Prothena has programs targeting TDP-43 aggregation in:
| Program | Target | Indication | Stage |
|---|---|---|---|
| PRX004 | TDP-43 | ALS/FTLD | Discovery |
| PRX012 | TDP-43 | ALS/FTLD | Preclinical |
| Attribute | Detail |
|---|---|
| Headquarters | San Francisco, California, USA |
| Founded | 2005 |
| CEO | Gene Kinney |
| Market Cap | ~$400 million |
| Employees | ~100 |
Prothena's platform is based on understanding protein misfolding and aggregation:
The company was originally founded to develop therapies based on research from Elan's amyloid research programs.
Prothena entered a significant partnership with Roche for PRX002 (anti-alpha-synuclein), with Roche gaining worldwide rights. This provided substantial upfront and milestone payments.